Consistent with this notion are data showing that treatment of patients with chronic lymphocytic leukemia (CLL) with anti-ROR1 mAb that can block ROR1 signaling, e.g., zilovertamab, formerly called cirmtuzumab or UC-961, significantly reduced cancer stemness and leukemia-cell expression of target genes induced by activated ERK1/2, NF-κB, and NRF2 relative to that of leukemia cells prior to therapy [13,14,15,16]. The gene discussed is ROR1; the disease is leukemia.